This study is being done to assess the effects of the CTP inhibitor on the function of your
platelets (cells within your blood that are involved in the formation of blood clots) and to
assess whether you have responded to the ticagrelor well enough to prevent the formation of
blood clots within the stent or site in which angioplasty was performed.
Recent studies have looked at how racial differences can affect platelet reactivity, the way
blood clots. But these studies have not looked at the way different racial backgrounds can
affect the way the blood forms clots. Minorities, such as African-Americans are
underrepresented. Therefore, we are conducting this platelet reactivity study to better
understand if there are differences in how this drug affects African-Americans from how they
affect Caucasian patients undergoing percutaneous coronary intervention and receiving
ticagrelor. These data will be compared to a historical control of Caucasian patients who
underwent similar platelet function testing.